Abstract:MiR-525-5p functions as an oncomiRNA or tumor suppressor, and has been reported in various cancer types, including laryngeal squamous cell carcinoma, glioma, breast cancer, and cervical cancer. However, the biological functions and precise mechanisms of miR-525-5p remain unclarified in Burkitt’s lymphoma (BL). This study aimed to explore the roles of miR-525-5p in BL, with the goal of ascertaining its regulatory effects on the nuclear factor-kappaB (NF-κB) signaling pathway by targeting Myeloid differentiation factor 88 (MyD88). The expression levels of miR-525-5p and MyD88 were measured by quantitative real-time PCR and immunohistochemical staining, respectively. The effects of miR-525-5p overexpression on BL cell proliferation, colony-forming, and migration were evaluated by cell counting kit-8, soft agar colony-forming, and transwell assays, while cell cycle and cell apoptosis were analyzed by flow cytometry. Possible interactions between miR-525-5p and MyD88 was examined via luciferase reporter assay. The expression of MyD88 and NF-κB signaling pathway-related proteins, including p65, p-p65, IκBa, and p-ΙκBa was determined by western blotting. BL cells overexpressing miR-525-5p were treated with phorbol 12-myristate 13-acetate (PMA), and Hoechst 33258 staining and Calcein AM/EthD-I staining were used to analyze the changes in chemotherapy sensitivity of BL cells to doxorubicin (DOX). Compared with reactive lymphoid hyperplasia, miR-525-5p was dramatically downregulated in BL tissues, while the rate of MyD88 protein positivity was significantly increased. Upregulation of miR-525-5p suppressed cell proliferation, colony-forming, and migration, induced cell cycle arrest and apoptosis, and enhanced the chemosensitivity to DOX in BL cells. MiR-525-5p targeted MyD88 to inhibit the activation of NF-κB signaling pathway. PMA treatment reactivated the NF-κB pathway and reversed apoptosis mediated by miR-525-5p overexpression. These findings revealed that miR-525-5p acts as a tumor suppressor, targeting MyD88 to modulate proliferation, cell cycle progression, and apoptosis in BL cells by regulation of NF-κB signaling pathway.

MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells

MiR-525-5p Modulates Cell Proliferation, Cell Cycle, and Apoptosis in Burkitt’s Lymphoma by Targeting MyD88 and Regulating the NF-κB Signaling Pathway

MicroRNA-155 Downregulation Promotes Cell Cycle Arrest and Apoptosis in Diffuse Large B-Cell Lymphoma

MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells

Overexpressed Mir-195 Attenuated Immune Escape of Diffuse Large B-cell Lymphoma by Targeting PD-L1.

Clinical and Prognostic Significance of Mir-155 and Mir-146A Expression Levels in Formalin-Fixed/paraffin-embedded Tissue of Patients with Diffuse Large B-cell Lymphoma.

MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8+ T lymphocytes in human diffuse large B cell lymphoma

Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells

[Role of miR-155 in pathogenesis of diffuse large B cell lymphoma and its possible mechanism].

Dynamically Expressed Microrna-15B Modulates the Activities of CD8 + T Lymphocytes in Mice with Lewis Lung Carcinoma

LINC00662 Promotes Melanoma Progression by Competitively Binding Mir-107 and Activating the Β-Catenin Signaling Pathway.

The recruitment of CD8+ T cells through YBX1 stabilization abrogates tumor intrinsic oncogenic role of MIR155HG in lung adenocarcinoma

Lna-Mediated Anti-Mir-155 Silencing In Low-Grade B-Cell Lymphomas

Serum Microrna Prognostic Model and Underlying Immune Alterations in Diffuse Large B Cell Lymphoma

Expression of MiR-296-5p in Diffuse Large B-Cell Lymphoma and Its Influence on Biological Behavior of Tumor Cells

Preliminary study on decreasing the expression of FOXP3 with miR-155 to inhibit diffuse large B-cell lymphoma.

MYC-dependent MiR-7-5p regulated apoptosis and autophagy in diffuse large B cell lymphoma by targeting AMBRA1

Novel Bio-Markers Latent Membrane Protein 1 and Microrna-155 for the Prognostic Prediction of Diffuse Large B Cell Lymphoma

MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma

[Expression of MiRNA-21 in Diffuse Large B Cell Lymphoma and Its Significance].

Mir-181A/b Significantly Enhances Drug Sensitivity in Chronic Lymphocytic Leukemia Cells Via Targeting Multiple Anti-Apoptosis Genes.